Cellectar Biosciences Inc. received the second phase of an NCI Fast-Track Small Business Innovation Research contract award of $2 million to support funding of a phase II study of the company’s lead product candidate, CLR 131, for the potential treatment of hematologic malignancies, including multiple myeloma.
The award will help fund a multi-center, open label study. The first phase of the NCI SBIR contract was focused on the pre-clinical development of CLR 125.
